Our LiquidBiopsy test allows for real-time monitoring of PD-L1 status on surviving circulating tumor cell clones to more accurately describe the present biologic state.
Westlake Village, CA (PRWEB)
August 08, 2017
Cynvenio Biosystems, Inc. a leader in liquid biopsy technology for cancer research and personalized medicine, today announced the launch of its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
PD-L1 has been detected to some degree in 50 to 90 percent of non-small cell lung cancers (NSCLC)✝, making it an important biomarker in immuno-oncology treatment decisions for lung cancer patients. Several checkpoint inhibitor drugs such as Keytruda, Tecentriq, and Opdivo have been recently approved by the FDA for patients expressing PD-L1 on tumor cells as research shows significant clinical benefit.
“PD-L1 is part of an adaptive dynamic pathway which can readily change as cancer progresses. Relying solely on the original PD-L1 status of a primary tumor specimen or biopsy may preclude patients who might otherwise benefit now for immunotherapy,” commented Paul Y. Song, MD, Cynvenio’s Chief Medical Officer. “Our LiquidBiopsy test allows for real-time monitoring of PD-L1 status on surviving circulating tumor cell clones to more accurately describe the present biologic state. This should allow for more precise patient selection and better outcomes with PD-1/PD-L1 immunotherapy which has shown great promise in lung cancer.”
“This new PD-L1 test analyzes actual tumor cells and cannot be performed using cell-free or ctDNA,” said Paul Dempsey,…